Format

Send to

Choose Destination
Retina. 2007 Nov-Dec;27(9):1180-6.

Intravitreal bevacizumab (avastin) injection as primary treatment of inflammatory choroidal neovascularization.

Author information

1
Department of Ophthalmology, Hospital Clinic de Barcelona, Universidad de Barcelona, Spain. amadan@clinic.ub.es

Abstract

OBJECTIVE:

To assess the effects of intravitreal bevacizumab injection as primary treatment of inflammatory choroidal neovascularization (CNV).

METHODS:

Data for nine consecutive patients with newly diagnosed inflammatory CNV who were treated with intravitreal bevacizumab (1.25 mg) injection were reviewed retrospectively. Main outcome measures were best-corrected visual acuity, foveal thickness measured by optical coherence tomography (OCT), and complete resolution of CNV.

RESULTS:

CNV resolved completely in 9 (100%) of 9 affected eyes. At the last examination, visual acuity was improved in 8 eyes (88.8%), stable in 1 (11.2%), and worse in 0. Over a mean follow-up of 7.1 months (range, 6-10 months), 7 eyes received 1 injection, 1 eye developed CNV recurrence and required a second injection, and 1 eye required a third injection. Foveal thickness by OCT decreased significantly (P = 0.049) after treatment.

CONCLUSION:

In this small case series of eyes with limited follow-up, intravitreal bevacizumab injection for treatment of inflammatory CNV was found to be safe and was associated with favorable visual outcomes for both subfoveal and juxtafoveal or extrafoveal inflammatory CNV.

PMID:
18046222
DOI:
10.1097/IAE.0b013e31815e9834
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center